BGB-11417-303
(CELESTIAL-RRCLL/CLL-RR1)

Figure 1: Study Schema



Abbreviations: BCL2i, B-cell lymphoma-2 inhibitor; BTKi, Bruton tyrosine kinase inhibitor; CLL, chronic lymphocytic leukemia; MRD, minimal residual disease; mut, mutation; n, total number of patients; O, obinutuzumab; R, rituximab; S, sonrotoclax; SLL, small lymphocytic lymphoma; V, venetoclax.

BGB-11417-303
(CELESTIAL-RRCLL/CLL-RR1)
Inclusion & Exclusion

Key Inclusion Criteria

- Adults (≥ 18 years) with a confirmed diagnosis of **relapsed and/or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)** per iwCLL 2018 criteria
- **≥ 1 prior systemic therapy** for CLL/SLL
- Disease **requiring treatment** according to iwCLL criteria
- **ECOG Performance Status 0–2**
- Adequate **bone marrow function**, including:
  - ANC ≥ 1.0 × 10^9/L (≥ 0.75 × 10^9/L if due to marrow involvement)
  - Platelets ≥ 75 × 10^9/L (≥ 30 × 10^9/L if due to marrow involvement)
  - Hemoglobin > 75 g/L
- Adequate **hepatic function**:
  - AST/ALT ≤ 2.5 × ULN
  - Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN with Gilbert syndrome)
- Adequate **renal function** (creatinine clearance or eGFR ≥ 30 mL/min)
- Life expectancy > 6 months
- Ability to provide **written informed consent**
- Willingness to comply with **protocol-required contraception measures**, where applicable

---

Key Exclusion Criteria

- Known **prolymphocytic leukemia** or suspected / confirmed **Richter's transformation**
- Prior **allogeneic stem cell transplant** with active graft-versus-host disease
- Recent **autologous transplant or CAR-T therapy** (< 3 months)
- Known **central nervous system involvement** by CLL/SLL
- History of confirmed **progressive multifocal leukoencephalopathy (PML)**
- **Clinically significant cardiovascular disease**, including:
    - Recent myocardial infarction
    - Unstable angina
    - NYHA class III/IV heart failure
    - Clinically significant arrhythmias or QTcF > 480 msec
- **Uncontrolled hypertension**
- Active, uncontrolled **infection**, including active hepatitis B, hepatitis C, or HIV
- Active symptomatic **COVID-19 infection**
- Prior or concurrent **malignancy** within the past 18 months (with protocol-defined exceptions)
- Known **hypersensitivity** to sonrotoclax, venetoclax, obinutuzumab, rituximab, or excipients
- **Pregnant or breastfeeding** patients
- Receipt of **live vaccines** within 4 weeks prior to first dose
- Receiving treatment with any **moderate or strong CYP3A4 inhibitor, or moderate or strong CYP3A4 inducer** (≤ 14 days or 5 half-lives, whichever is shorter) before the first dose of sonrotoclax/venetoclax, or requiring ongoing treatment with a moderate or strong CYP3A inhibitor or a moderate/strong CYP3A inducer at the study entry. (Contraindication: **Concomitant use of strong CYP3A inhibitors at initiation and during the dose-titration phase**.)
- Inability to swallow oral medication or clinically significant **gastrointestinal disorders** affecting absorption

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.